Home » Tenders » Europe » Germany » Openhouse Procedure - Div. Active Ingredients from 01.10.2022 Tender, Germany - 68352660

Openhouse Procedure - Div. Active Ingredients from 01.10.2022 Tender, Germany - 68352660

Download Documents

AOK RHINELAND/HAMBURG - THE HEALTH INSURANCE FUND has floated a tender for Openhouse Procedure - Div. Active Ingredients from 01.10.2022. The project location is Germany and the tender is closing on 05 Sep 2024. The tender notice number is 349740-2022, while the TOT Ref Number is 68352660. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : Germany

Summary : Openhouse Procedure - Div. Active Ingredients from 01.10.2022

Deadline : 05 Sep 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 68352660

Document Ref. No. : 349740-2022

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Tender Details

Document Type: Corrigendum/Additional Information (Please Refer Tender Document)

Title: Openhouse procedure - Div. Active ingredients from 01.10.2022

Reference Number: 2022-06 ARZEICEMENT Department

Contract type: Supplies

Description: Completion of non-exclusive discount agreements according to § 130 a (8) SGB V with any final option within the framework of so-called "OpenHouse methods" for various drug active ingredients with the earliest possible start of the contract on October 1, 2022.

.

The concrete drug active substances and the respective start of the contract can be found in the current list of drugs in the project space of the award portal DTVP in the "Tender documents" section.

.

On October 1st, 2022, contracts for the following active ingredients are offered:

.

Abacavir / Lamivudin / Zidovudin

Acetylcystein_non-rx non-rx

Acetylcystein_rx rx

Acetylsalicylic acid exclusively in accordance with Appendix 1 AM-RL G-BA. Acitretin

Adefovir Dipivoxil

Alitretinoin

Amifampridin

Anagrelid except N3 packs of the DAR HKP with 0.5 mg effectiveness

Aripiprazole with the exception of DAR tablets/melt tablets and solutions to the input ...